Why the study?
Is isradipine effective and safe as a first-line monotherapy for the treatment of hypertension?
Is isradipine effective and safe as a first-line monotherapy for the treatment of hypertension?
Isradipine is an effective and safe first-line calcium channel blocker for hypertension with a favorable metabolic and safety profile.
Answers are grounded in this paper and cite their sources.
May support isradipine monotherapy in select patients; leaves open need for RCTs versus modern agents.
Isradipine (DynaCirc, PK 200-110) is a new calcium channel blocker of the dihydropyridine class. In controlled, double-blind, clinical trials isradipine is an effective first-line monotherapeutic agent in the treatment of hypertension, regardless of patient age or race. Isradipine is safe and well tolerated, with few adverse effects reported, and does not cause significant changes in cardiac conduction or the force of cardiac contraction. In addition, it does not adversely affect the lipid profile, carbohydrate tolerance, or renal function. Long-term experience with isradipine indicates that the antihypertensive efficacy is maintained without problems of tachycardia or tachyphylaxis.
No takes yet. Share an insight, caveat, or question.
Donald G. Vidt (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: